| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genes, BRCA1 | 55 | 2020 | 781 | 7.120 |
Why?
|
| Genes, BRCA2 | 47 | 2020 | 618 | 6.670 |
Why?
|
| Prostatic Neoplasms | 113 | 2024 | 11124 | 6.380 |
Why?
|
| BRCA2 Protein | 41 | 2022 | 794 | 5.480 |
Why?
|
| BRCA1 Protein | 43 | 2022 | 1149 | 5.320 |
Why?
|
| Ovariectomy | 21 | 2016 | 661 | 3.800 |
Why?
|
| Genetic Predisposition to Disease | 148 | 2023 | 17446 | 3.700 |
Why?
|
| Breast Neoplasms | 125 | 2023 | 20822 | 3.190 |
Why?
|
| Ovarian Neoplasms | 48 | 2023 | 4838 | 2.900 |
Why?
|
| Neoplasms | 67 | 2024 | 21683 | 2.530 |
Why?
|
| Heterozygote | 52 | 2022 | 2804 | 2.320 |
Why?
|
| Cytochrome P-450 Enzyme System | 16 | 2014 | 419 | 2.300 |
Why?
|
| Germ-Line Mutation | 32 | 2022 | 1788 | 2.000 |
Why?
|
| Polymorphism, Single Nucleotide | 84 | 2023 | 15519 | 1.930 |
Why?
|
| Mutation | 72 | 2022 | 29786 | 1.780 |
Why?
|
| Genotype | 91 | 2019 | 12951 | 1.710 |
Why?
|
| Prostate-Specific Antigen | 26 | 2024 | 2494 | 1.650 |
Why?
|
| Endometrial Neoplasms | 21 | 2023 | 1353 | 1.580 |
Why?
|
| Health Status Disparities | 12 | 2023 | 1797 | 1.570 |
Why?
|
| Residence Characteristics | 8 | 2023 | 2050 | 1.430 |
Why?
|
| Genetic Variation | 33 | 2021 | 6544 | 1.370 |
Why?
|
| Prostate | 14 | 2024 | 1774 | 1.340 |
Why?
|
| Glutathione Transferase | 12 | 2011 | 595 | 1.340 |
Why?
|
| Prostatectomy | 16 | 2022 | 1890 | 1.320 |
Why?
|
| Social Class | 7 | 2023 | 1999 | 1.320 |
Why?
|
| Genome-Wide Association Study | 43 | 2023 | 12261 | 1.280 |
Why?
|
| Humans | 452 | 2024 | 744343 | 1.210 |
Why?
|
| Cytochrome P-450 CYP3A | 15 | 2012 | 115 | 1.180 |
Why?
|
| Mastectomy | 7 | 2022 | 1793 | 1.130 |
Why?
|
| Case-Control Studies | 84 | 2022 | 21746 | 1.120 |
Why?
|
| Genetics, Population | 12 | 2020 | 934 | 1.110 |
Why?
|
| Alleles | 42 | 2019 | 6933 | 1.080 |
Why?
|
| Polymorphism, Genetic | 32 | 2013 | 4328 | 1.060 |
Why?
|
| Estrogen Replacement Therapy | 7 | 2022 | 1203 | 1.000 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 6 | 2012 | 257 | 0.990 |
Why?
|
| Receptor, Melanocortin, Type 1 | 6 | 2015 | 76 | 0.990 |
Why?
|
| Genomics | 12 | 2023 | 5720 | 0.970 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 2 | 2023 | 30 | 0.960 |
Why?
|
| Early Detection of Cancer | 18 | 2024 | 3086 | 0.950 |
Why?
|
| Healthcare Disparities | 9 | 2023 | 3158 | 0.930 |
Why?
|
| Risk Factors | 120 | 2024 | 72290 | 0.900 |
Why?
|
| Male | 200 | 2024 | 350118 | 0.850 |
Why?
|
| Middle Aged | 190 | 2023 | 213383 | 0.840 |
Why?
|
| Community-Institutional Relations | 1 | 2023 | 204 | 0.820 |
Why?
|
| Gene Frequency | 29 | 2018 | 3588 | 0.810 |
Why?
|
| Environment | 3 | 2023 | 1124 | 0.810 |
Why?
|
| Periodicals as Topic | 5 | 2011 | 1432 | 0.780 |
Why?
|
| Genetic Markers | 18 | 2012 | 2634 | 0.780 |
Why?
|
| Germ Cells | 4 | 2023 | 631 | 0.780 |
Why?
|
| Whiplash Injuries | 2 | 2013 | 15 | 0.750 |
Why?
|
| Hot Flashes | 3 | 2014 | 317 | 0.750 |
Why?
|
| Prognosis | 43 | 2023 | 29063 | 0.740 |
Why?
|
| Catechol O-Methyltransferase | 4 | 2012 | 245 | 0.730 |
Why?
|
| Risk Reduction Behavior | 10 | 2017 | 1125 | 0.730 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 214 | 0.730 |
Why?
|
| Female | 237 | 2023 | 380194 | 0.720 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2020 | 76 | 0.710 |
Why?
|
| Neoplasm Proteins | 16 | 2016 | 3703 | 0.700 |
Why?
|
| Receptors, Progesterone | 10 | 2014 | 1097 | 0.690 |
Why?
|
| Aged | 134 | 2024 | 163280 | 0.680 |
Why?
|
| Estrogens | 8 | 2022 | 1566 | 0.680 |
Why?
|
| Odds Ratio | 37 | 2019 | 9849 | 0.670 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2020 | 1581 | 0.660 |
Why?
|
| Pennsylvania | 8 | 2021 | 613 | 0.660 |
Why?
|
| Molecular Epidemiology | 7 | 2010 | 468 | 0.650 |
Why?
|
| Haplotypes | 14 | 2015 | 2779 | 0.630 |
Why?
|
| Epidemiology | 4 | 2019 | 287 | 0.630 |
Why?
|
| Melanoma | 20 | 2015 | 5510 | 0.620 |
Why?
|
| Carcinoma | 8 | 2021 | 2375 | 0.620 |
Why?
|
| Population Surveillance | 6 | 2019 | 2616 | 0.620 |
Why?
|
| Epidemiologic Studies | 4 | 2013 | 676 | 0.610 |
Why?
|
| Incidence | 34 | 2023 | 20947 | 0.600 |
Why?
|
| Mixed Function Oxygenases | 4 | 2000 | 272 | 0.600 |
Why?
|
| Pathology, Molecular | 4 | 2022 | 326 | 0.590 |
Why?
|
| Arylsulfotransferase | 5 | 2010 | 28 | 0.580 |
Why?
|
| Adult | 143 | 2023 | 214055 | 0.580 |
Why?
|
| Africa South of the Sahara | 7 | 2023 | 724 | 0.570 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2024 | 177 | 0.570 |
Why?
|
| Genetic Testing | 16 | 2023 | 3444 | 0.560 |
Why?
|
| Propensity Score | 4 | 2022 | 1781 | 0.560 |
Why?
|
| Health Facilities | 2 | 2022 | 573 | 0.550 |
Why?
|
| Primary Prevention | 4 | 2018 | 1167 | 0.540 |
Why?
|
| Publishing | 3 | 2008 | 833 | 0.530 |
Why?
|
| DNA, Mitochondrial | 3 | 2017 | 817 | 0.530 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 940 | 0.530 |
Why?
|
| Biomedical Research | 8 | 2018 | 3309 | 0.530 |
Why?
|
| Cytochrome P-450 CYP1A2 | 3 | 2012 | 68 | 0.510 |
Why?
|
| Risk Assessment | 32 | 2022 | 23338 | 0.510 |
Why?
|
| Socioeconomic Factors | 10 | 2024 | 7785 | 0.510 |
Why?
|
| Endoribonucleases | 2 | 2008 | 229 | 0.500 |
Why?
|
| Skin Neoplasms | 16 | 2015 | 5686 | 0.500 |
Why?
|
| Multiple Myeloma | 6 | 2024 | 5181 | 0.500 |
Why?
|
| Genetic Association Studies | 12 | 2021 | 2703 | 0.500 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2022 | 3479 | 0.490 |
Why?
|
| Philadelphia | 7 | 2013 | 266 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2022 | 9239 | 0.490 |
Why?
|
| Jews | 7 | 2012 | 385 | 0.480 |
Why?
|
| Genetic Linkage | 16 | 2004 | 2421 | 0.470 |
Why?
|
| Fallopian Tubes | 3 | 2010 | 182 | 0.470 |
Why?
|
| Life Style | 3 | 2023 | 3835 | 0.470 |
Why?
|
| Risk | 27 | 2022 | 9687 | 0.470 |
Why?
|
| Receptors, Androgen | 5 | 2020 | 1058 | 0.470 |
Why?
|
| Body Mass Index | 11 | 2021 | 12720 | 0.470 |
Why?
|
| Polymerase Chain Reaction | 18 | 2015 | 6171 | 0.470 |
Why?
|
| Smoking | 12 | 2014 | 8987 | 0.460 |
Why?
|
| Telomere | 2 | 2017 | 910 | 0.450 |
Why?
|
| Postmenopause | 5 | 2012 | 2461 | 0.450 |
Why?
|
| Developing Countries | 5 | 2021 | 2815 | 0.450 |
Why?
|
| Obesity | 14 | 2024 | 12745 | 0.450 |
Why?
|
| Aromatase | 3 | 2011 | 146 | 0.440 |
Why?
|
| Cohort Studies | 43 | 2024 | 40561 | 0.440 |
Why?
|
| Population Groups | 3 | 2022 | 209 | 0.430 |
Why?
|
| Genetic Loci | 12 | 2020 | 2575 | 0.430 |
Why?
|
| Breast Neoplasms, Male | 3 | 2022 | 210 | 0.430 |
Why?
|
| Neoplasm Invasiveness | 6 | 2017 | 3616 | 0.420 |
Why?
|
| General Practitioners | 1 | 2013 | 103 | 0.420 |
Why?
|
| Internationality | 1 | 2018 | 1003 | 0.420 |
Why?
|
| Aged, 80 and over | 45 | 2023 | 57776 | 0.420 |
Why?
|
| Logistic Models | 18 | 2019 | 13408 | 0.420 |
Why?
|
| Health Services Accessibility | 6 | 2023 | 5137 | 0.420 |
Why?
|
| Senegal | 7 | 2021 | 294 | 0.410 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 2 | 2008 | 58 | 0.410 |
Why?
|
| DNA | 10 | 2015 | 7301 | 0.410 |
Why?
|
| Mass Screening | 12 | 2024 | 5255 | 0.410 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2010 | 188 | 0.400 |
Why?
|
| Research Personnel | 2 | 2015 | 573 | 0.400 |
Why?
|
| Income | 4 | 2024 | 1913 | 0.390 |
Why?
|
| Models, Statistical | 9 | 2020 | 5102 | 0.390 |
Why?
|
| Public Health | 6 | 2023 | 2603 | 0.390 |
Why?
|
| Health Promotion | 1 | 2023 | 2205 | 0.390 |
Why?
|
| Prospective Studies | 23 | 2023 | 53288 | 0.390 |
Why?
|
| Epidemiologic Methods | 4 | 2010 | 1364 | 0.390 |
Why?
|
| United States | 44 | 2024 | 69872 | 0.390 |
Why?
|
| Scavenger Receptors, Class A | 2 | 2008 | 54 | 0.380 |
Why?
|
| Postal Service | 1 | 2011 | 96 | 0.380 |
Why?
|
| Haiti | 3 | 2022 | 553 | 0.380 |
Why?
|
| Seminal Vesicles | 2 | 2014 | 101 | 0.380 |
Why?
|
| Transcription Factors | 19 | 2015 | 12208 | 0.370 |
Why?
|
| Watchful Waiting | 3 | 2019 | 492 | 0.370 |
Why?
|
| Penetrance | 4 | 2018 | 381 | 0.370 |
Why?
|
| Computer-Assisted Instruction | 1 | 2013 | 365 | 0.370 |
Why?
|
| Models, Genetic | 7 | 2009 | 3494 | 0.360 |
Why?
|
| Receptors, Estrogen | 11 | 2017 | 2187 | 0.360 |
Why?
|
| Neoplasm Staging | 18 | 2019 | 11031 | 0.350 |
Why?
|
| Delivery of Health Care | 6 | 2023 | 5319 | 0.350 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2011 | 2849 | 0.350 |
Why?
|
| Paraproteinemias | 2 | 2022 | 246 | 0.350 |
Why?
|
| Prejudice | 1 | 2014 | 570 | 0.350 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2012 | 284 | 0.350 |
Why?
|
| Perimenopause | 1 | 2010 | 139 | 0.340 |
Why?
|
| Phenotype | 27 | 2020 | 16365 | 0.340 |
Why?
|
| Precancerous Conditions | 4 | 2020 | 975 | 0.340 |
Why?
|
| Reproductive History | 3 | 2014 | 209 | 0.340 |
Why?
|
| Decision Trees | 1 | 2011 | 506 | 0.340 |
Why?
|
| Alopecia | 1 | 2013 | 382 | 0.340 |
Why?
|
| Oncogene Proteins | 2 | 2020 | 749 | 0.330 |
Why?
|
| Membrane Transport Proteins | 2 | 2006 | 1028 | 0.330 |
Why?
|
| Urban Population | 1 | 2017 | 2021 | 0.330 |
Why?
|
| Group Processes | 1 | 2010 | 225 | 0.330 |
Why?
|
| Environmental Exposure | 4 | 2020 | 4234 | 0.330 |
Why?
|
| Genetic Counseling | 5 | 2020 | 600 | 0.320 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2008 | 65 | 0.320 |
Why?
|
| National Cancer Institute (U.S.) | 5 | 2023 | 288 | 0.310 |
Why?
|
| South Africa | 7 | 2022 | 1731 | 0.310 |
Why?
|
| Medical Oncology | 5 | 2023 | 2265 | 0.310 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 840 | 0.310 |
Why?
|
| Intermediate Filament Proteins | 3 | 2014 | 269 | 0.310 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2011 | 1519 | 0.310 |
Why?
|
| Progestins | 2 | 2007 | 306 | 0.310 |
Why?
|
| North America | 7 | 2012 | 1249 | 0.310 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2008 | 415 | 0.300 |
Why?
|
| Science | 1 | 2010 | 241 | 0.300 |
Why?
|
| Follow-Up Studies | 21 | 2023 | 39050 | 0.290 |
Why?
|
| Social Support | 1 | 2017 | 2118 | 0.290 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2010 | 324 | 0.290 |
Why?
|
| Phytoestrogens | 1 | 2007 | 61 | 0.290 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2018 | 2245 | 0.290 |
Why?
|
| Eye Color | 3 | 2006 | 36 | 0.290 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2011 | 430 | 0.290 |
Why?
|
| Pedigree | 24 | 2017 | 4644 | 0.280 |
Why?
|
| Disease-Free Survival | 8 | 2020 | 6895 | 0.280 |
Why?
|
| Geography | 4 | 2018 | 669 | 0.280 |
Why?
|
| Caribbean Region | 3 | 2022 | 194 | 0.280 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2011 | 62 | 0.280 |
Why?
|
| Dermatitis, Atopic | 4 | 2014 | 654 | 0.280 |
Why?
|
| Organic Anion Transporters | 1 | 2006 | 100 | 0.270 |
Why?
|
| Europe | 6 | 2019 | 3339 | 0.270 |
Why?
|
| Salpingectomy | 2 | 2016 | 53 | 0.270 |
Why?
|
| Ribosomal Proteins | 1 | 2008 | 360 | 0.270 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2011 | 1861 | 0.270 |
Why?
|
| Interdisciplinary Communication | 3 | 2010 | 950 | 0.260 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2022 | 2020 | 0.260 |
Why?
|
| DNA Mutational Analysis | 9 | 2010 | 4186 | 0.260 |
Why?
|
| Arylamine N-Acetyltransferase | 3 | 2004 | 86 | 0.260 |
Why?
|
| Membrane Proteins | 6 | 2015 | 7880 | 0.260 |
Why?
|
| Penicillins | 1 | 2008 | 380 | 0.260 |
Why?
|
| Mendelian Randomization Analysis | 3 | 2020 | 967 | 0.260 |
Why?
|
| Multigene Family | 2 | 2020 | 1102 | 0.260 |
Why?
|
| DNA Repair | 6 | 2021 | 2046 | 0.260 |
Why?
|
| Androgens | 2 | 2013 | 1281 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 8428 | 0.260 |
Why?
|
| Biopsy | 6 | 2023 | 6756 | 0.250 |
Why?
|
| Phytotherapy | 1 | 2007 | 298 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 11 | 5 | 2016 | 417 | 0.250 |
Why?
|
| Promoter Regions, Genetic | 3 | 2021 | 5867 | 0.250 |
Why?
|
| Algorithms | 10 | 2018 | 13881 | 0.250 |
Why?
|
| Confidence Intervals | 8 | 2013 | 2971 | 0.250 |
Why?
|
| Interleukin-4 | 1 | 2008 | 1147 | 0.250 |
Why?
|
| Acetyltransferases | 1 | 2005 | 234 | 0.240 |
Why?
|
| Prostatic Hyperplasia | 1 | 2008 | 523 | 0.240 |
Why?
|
| Age Factors | 21 | 2022 | 18370 | 0.240 |
Why?
|
| Peritoneal Neoplasms | 2 | 2018 | 665 | 0.240 |
Why?
|
| Proto-Oncogenes | 3 | 2001 | 321 | 0.240 |
Why?
|
| Neoplasms, Multiple Primary | 6 | 2007 | 604 | 0.240 |
Why?
|
| Sunlight | 4 | 2010 | 325 | 0.240 |
Why?
|
| Biological Products | 1 | 2013 | 860 | 0.230 |
Why?
|
| Tobacco Use Disorder | 1 | 2009 | 688 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 7279 | 0.230 |
Why?
|
| Genome, Human | 11 | 2020 | 4420 | 0.230 |
Why?
|
| Interleukin-10 | 2 | 2008 | 1200 | 0.230 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2759 | 0.230 |
Why?
|
| Africa | 4 | 2018 | 673 | 0.230 |
Why?
|
| Trinucleotide Repeats | 3 | 2011 | 261 | 0.230 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 675 | 0.220 |
Why?
|
| Polymorphism, Restriction Fragment Length | 7 | 2011 | 768 | 0.220 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2006 | 651 | 0.220 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2266 | 0.220 |
Why?
|
| Young Adult | 22 | 2022 | 56430 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2002 | 373 | 0.220 |
Why?
|
| Eating | 1 | 2010 | 1536 | 0.220 |
Why?
|
| Telomerase | 3 | 2013 | 730 | 0.220 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2003 | 115 | 0.220 |
Why?
|
| Antiporters | 3 | 1993 | 277 | 0.220 |
Why?
|
| Androgen Antagonists | 2 | 2023 | 1377 | 0.220 |
Why?
|
| Age of Onset | 8 | 2015 | 3271 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2023 | 3597 | 0.220 |
Why?
|
| DNA-Binding Proteins | 11 | 2014 | 9648 | 0.220 |
Why?
|
| Skin Pigmentation | 5 | 2015 | 282 | 0.220 |
Why?
|
| Proportional Hazards Models | 11 | 2021 | 12354 | 0.210 |
Why?
|
| Body Height | 2 | 2019 | 1577 | 0.210 |
Why?
|
| Skin Diseases | 1 | 2011 | 1065 | 0.210 |
Why?
|
| Retrospective Studies | 25 | 2023 | 77449 | 0.210 |
Why?
|
| Genetic Techniques | 1 | 2005 | 435 | 0.210 |
Why?
|
| Prevalence | 12 | 2022 | 15226 | 0.210 |
Why?
|
| Tumor Microenvironment | 5 | 2022 | 3586 | 0.210 |
Why?
|
| Health Policy | 2 | 2021 | 2661 | 0.200 |
Why?
|
| Serine Endopeptidases | 2 | 2021 | 1072 | 0.200 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2021 | 70 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 17 | 6 | 2011 | 437 | 0.200 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2021 | 29 | 0.200 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2001 | 431 | 0.200 |
Why?
|
| Sulfotransferases | 3 | 2010 | 151 | 0.200 |
Why?
|
| Rwanda | 2 | 2022 | 703 | 0.200 |
Why?
|
| Agouti Signaling Protein | 3 | 2014 | 21 | 0.200 |
Why?
|
| Receptors, Immunologic | 2 | 2005 | 1423 | 0.200 |
Why?
|
| Pigmentation | 1 | 2002 | 148 | 0.200 |
Why?
|
| Genetic Heterogeneity | 3 | 2007 | 733 | 0.200 |
Why?
|
| Predictive Value of Tests | 11 | 2022 | 15076 | 0.200 |
Why?
|
| Carrier Proteins | 6 | 2015 | 5021 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 2 | 2010 | 2007 | 0.200 |
Why?
|
| Inflammation | 4 | 2023 | 10638 | 0.200 |
Why?
|
| Treatment Failure | 3 | 2015 | 2618 | 0.200 |
Why?
|
| Privacy | 1 | 2023 | 239 | 0.200 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 640 | 0.190 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 1956 | 0.190 |
Why?
|
| New South Wales | 2 | 2013 | 66 | 0.190 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 25043 | 0.190 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2015 | 484 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2023 | 2948 | 0.190 |
Why?
|
| Hydroxytestosterones | 1 | 2000 | 3 | 0.190 |
Why?
|
| Likelihood Functions | 4 | 2015 | 1005 | 0.180 |
Why?
|
| Albinism, Ocular | 2 | 1997 | 8 | 0.180 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2014 | 1101 | 0.180 |
Why?
|
| Access to Information | 1 | 2023 | 320 | 0.180 |
Why?
|
| Survival Rate | 10 | 2021 | 12788 | 0.180 |
Why?
|
| Biological Specimen Banks | 2 | 2022 | 711 | 0.180 |
Why?
|
| Probability | 9 | 2009 | 2505 | 0.180 |
Why?
|
| Loss of Heterozygosity | 5 | 2016 | 684 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 931 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2012 | 367 | 0.180 |
Why?
|
| Rad51 Recombinase | 3 | 2011 | 189 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 3 | 2022 | 5256 | 0.180 |
Why?
|
| Hormone Replacement Therapy | 1 | 2005 | 745 | 0.180 |
Why?
|
| Women's Health | 2 | 2017 | 2034 | 0.180 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 211 | 0.170 |
Why?
|
| Oxidoreductases | 1 | 2002 | 424 | 0.170 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 884 | 0.170 |
Why?
|
| Exons | 7 | 2016 | 2437 | 0.170 |
Why?
|
| Podophyllotoxin | 1 | 1998 | 21 | 0.170 |
Why?
|
| Repressor Proteins | 4 | 2020 | 3023 | 0.170 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2021 | 849 | 0.170 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 1641 | 0.170 |
Why?
|
| Meta-Analysis as Topic | 5 | 2018 | 1344 | 0.170 |
Why?
|
| Databases, Genetic | 3 | 2019 | 1783 | 0.160 |
Why?
|
| Obesity, Abdominal | 1 | 2021 | 361 | 0.160 |
Why?
|
| Linkage Disequilibrium | 10 | 2013 | 1997 | 0.160 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2005 | 1676 | 0.160 |
Why?
|
| Glutathione S-Transferase pi | 4 | 2015 | 97 | 0.160 |
Why?
|
| Trans-Activators | 3 | 2015 | 2924 | 0.160 |
Why?
|
| Carcinogens, Environmental | 2 | 2004 | 67 | 0.160 |
Why?
|
| Methotrexate | 1 | 2005 | 1727 | 0.160 |
Why?
|
| Australia | 6 | 2023 | 1170 | 0.160 |
Why?
|
| Adenocarcinoma | 4 | 2019 | 6364 | 0.160 |
Why?
|
| Neuropeptide Y | 1 | 2019 | 200 | 0.160 |
Why?
|
| Baltimore | 1 | 2018 | 231 | 0.160 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 2015 | 0.160 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 193 | 0.160 |
Why?
|
| Kenya | 1 | 2020 | 685 | 0.160 |
Why?
|
| Hair Color | 3 | 2010 | 136 | 0.150 |
Why?
|
| Menopause | 3 | 2019 | 1626 | 0.150 |
Why?
|
| Age Distribution | 5 | 2020 | 2902 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2013 | 4245 | 0.150 |
Why?
|
| Chromosomal Instability | 1 | 2018 | 184 | 0.150 |
Why?
|
| Gene Deletion | 4 | 2011 | 2751 | 0.150 |
Why?
|
| Botswana | 4 | 2022 | 1040 | 0.150 |
Why?
|
| Feeding Behavior | 1 | 2010 | 3188 | 0.150 |
Why?
|
| Multifactorial Inheritance | 3 | 2022 | 1194 | 0.150 |
Why?
|
| Travel | 1 | 2023 | 788 | 0.150 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2012 | 712 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 1 | 2022 | 523 | 0.140 |
Why?
|
| Disease Progression | 10 | 2021 | 13284 | 0.140 |
Why?
|
| Morbidity | 2 | 2013 | 1769 | 0.140 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 1378 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2003 | 1097 | 0.140 |
Why?
|
| Founder Effect | 3 | 2012 | 189 | 0.140 |
Why?
|
| Informed Consent | 1 | 2023 | 995 | 0.140 |
Why?
|
| Mouth Mucosa | 1 | 1999 | 434 | 0.140 |
Why?
|
| Markov Chains | 1 | 2020 | 969 | 0.140 |
Why?
|
| X Chromosome | 2 | 1997 | 814 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 16 | 4 | 2013 | 354 | 0.140 |
Why?
|
| Adolescent | 23 | 2020 | 85781 | 0.140 |
Why?
|
| Tanzania | 1 | 2020 | 1346 | 0.140 |
Why?
|
| Health Status | 2 | 2006 | 4034 | 0.130 |
Why?
|
| ROC Curve | 4 | 2023 | 3527 | 0.130 |
Why?
|
| Sex Distribution | 3 | 2018 | 2297 | 0.130 |
Why?
|
| Cholesterol, HDL | 2 | 2020 | 1814 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 323 | 0.130 |
Why?
|
| Glucuronosyltransferase | 2 | 2006 | 128 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 2 | 2006 | 1061 | 0.130 |
Why?
|
| SEER Program | 4 | 2019 | 1508 | 0.130 |
Why?
|
| Life Expectancy | 1 | 2022 | 1184 | 0.130 |
Why?
|
| Advisory Committees | 1 | 2019 | 775 | 0.130 |
Why?
|
| Genes, Mitochondrial | 1 | 2015 | 61 | 0.130 |
Why?
|
| Bayes Theorem | 4 | 2018 | 2309 | 0.130 |
Why?
|
| Immunohistochemistry | 7 | 2021 | 11366 | 0.130 |
Why?
|
| Chromosome Mapping | 10 | 2017 | 4740 | 0.130 |
Why?
|
| Decision Making | 4 | 2020 | 3887 | 0.130 |
Why?
|
| Carcinoma, Lobular | 2 | 2014 | 484 | 0.130 |
Why?
|
| Hypertension | 7 | 2014 | 8480 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2007 | 705 | 0.130 |
Why?
|
| Individuality | 1 | 1996 | 307 | 0.130 |
Why?
|
| Preventive Health Services | 1 | 2019 | 575 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1998 | 624 | 0.120 |
Why?
|
| Monte Carlo Method | 1 | 2020 | 1254 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 2513 | 0.120 |
Why?
|
| Sensitivity and Specificity | 8 | 2022 | 14722 | 0.120 |
Why?
|
| Specimen Handling | 1 | 1999 | 694 | 0.120 |
Why?
|
| Stromal Cells | 1 | 2020 | 1355 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2007 | 3297 | 0.120 |
Why?
|
| Nuclear Receptor Coactivator 3 | 2 | 2005 | 53 | 0.120 |
Why?
|
| Mass Spectrometry | 2 | 2022 | 2203 | 0.120 |
Why?
|
| Receptor, erbB-2 | 4 | 2014 | 2416 | 0.120 |
Why?
|
| Interleukin-16 | 1 | 2013 | 33 | 0.120 |
Why?
|
| Psychology | 1 | 2016 | 356 | 0.120 |
Why?
|
| Ghana | 3 | 2021 | 286 | 0.120 |
Why?
|
| Diet | 2 | 2022 | 7939 | 0.120 |
Why?
|
| Proteins | 3 | 2013 | 6103 | 0.110 |
Why?
|
| Leukemia | 2 | 1998 | 1511 | 0.110 |
Why?
|
| DNA Glycosylases | 1 | 2014 | 128 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2005 | 2071 | 0.110 |
Why?
|
| Family | 3 | 2018 | 3147 | 0.110 |
Why?
|
| Reference Values | 3 | 2010 | 4982 | 0.110 |
Why?
|
| Maternal Age | 2 | 2014 | 802 | 0.110 |
Why?
|
| S100 Proteins | 1 | 2013 | 259 | 0.110 |
Why?
|
| Clubfoot | 1 | 1993 | 63 | 0.110 |
Why?
|
| Parasites | 1 | 2015 | 163 | 0.110 |
Why?
|
| Selection, Genetic | 1 | 2018 | 914 | 0.110 |
Why?
|
| Reproducibility of Results | 10 | 2014 | 19905 | 0.110 |
Why?
|
| Directive Counseling | 1 | 2014 | 166 | 0.110 |
Why?
|
| Metformin | 1 | 2020 | 835 | 0.110 |
Why?
|
| Fungi | 1 | 2015 | 327 | 0.110 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2012 | 563 | 0.110 |
Why?
|
| Proteomics | 2 | 2017 | 3638 | 0.110 |
Why?
|
| Cytochrome P-450 CYP1A1 | 2 | 2006 | 91 | 0.110 |
Why?
|
| Registries | 6 | 2023 | 8089 | 0.110 |
Why?
|
| Progesterone | 2 | 2007 | 776 | 0.110 |
Why?
|
| Triglycerides | 1 | 2020 | 2454 | 0.110 |
Why?
|
| Educational Status | 2 | 2023 | 2540 | 0.110 |
Why?
|
| Contraceptives, Oral | 4 | 2014 | 564 | 0.100 |
Why?
|
| Nucleotides | 1 | 2015 | 464 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2011 | 460 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 6 | 4 | 2016 | 380 | 0.100 |
Why?
|
| DNA Primers | 4 | 2007 | 2892 | 0.100 |
Why?
|
| Homozygote | 3 | 2013 | 1785 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 4851 | 0.100 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 12245 | 0.100 |
Why?
|
| Chromosomes, Human | 2 | 2011 | 457 | 0.100 |
Why?
|
| Lymphatic Metastasis | 4 | 2010 | 2924 | 0.100 |
Why?
|
| India | 2 | 2008 | 2197 | 0.100 |
Why?
|
| Viruses | 1 | 2015 | 374 | 0.100 |
Why?
|
| Depression | 2 | 2012 | 7766 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6538 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 2282 | 0.100 |
Why?
|
| Epistasis, Genetic | 2 | 2011 | 365 | 0.100 |
Why?
|
| Neuroblastoma | 4 | 2002 | 1226 | 0.100 |
Why?
|
| Attitude to Health | 2 | 2019 | 2052 | 0.100 |
Why?
|
| Polychondritis, Relapsing | 1 | 2011 | 28 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 15540 | 0.100 |
Why?
|
| Caspase 10 | 1 | 2010 | 4 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2010 | 2539 | 0.100 |
Why?
|
| Research Report | 1 | 2014 | 355 | 0.100 |
Why?
|
| Osteogenesis Imperfecta | 1 | 2012 | 83 | 0.100 |
Why?
|
| Data Mining | 2 | 2019 | 537 | 0.100 |
Why?
|
| Linear Models | 3 | 2017 | 5952 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 2356 | 0.100 |
Why?
|
| Family Health | 5 | 2008 | 1282 | 0.090 |
Why?
|
| Disease Susceptibility | 6 | 2022 | 1782 | 0.090 |
Why?
|
| Transcription, Genetic | 2 | 2015 | 7722 | 0.090 |
Why?
|
| Luciferases | 3 | 2013 | 733 | 0.090 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2013 | 271 | 0.090 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2011 | 129 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2012 | 462 | 0.090 |
Why?
|
| Sex Factors | 4 | 2013 | 10397 | 0.090 |
Why?
|
| Smad3 Protein | 1 | 2010 | 180 | 0.090 |
Why?
|
| Caspase 8 | 1 | 2010 | 195 | 0.090 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 2011 | 798 | 0.090 |
Why?
|
| Survival Analysis | 6 | 2019 | 10252 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 2916 | 0.090 |
Why?
|
| Gene Pool | 1 | 2009 | 35 | 0.090 |
Why?
|
| Base Sequence | 6 | 2011 | 12797 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2023 | 3923 | 0.090 |
Why?
|
| Quality of Life | 4 | 2019 | 12804 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2012 | 535 | 0.090 |
Why?
|
| HIV Infections | 3 | 2022 | 16718 | 0.090 |
Why?
|
| Gene Amplification | 1 | 1994 | 1063 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2023 | 3528 | 0.090 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2011 | 271 | 0.090 |
Why?
|
| Quantitative Trait Loci | 4 | 2020 | 2019 | 0.090 |
Why?
|
| Aspirin | 1 | 2021 | 3282 | 0.090 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2009 | 72 | 0.090 |
Why?
|
| Organizational Objectives | 2 | 2008 | 438 | 0.090 |
Why?
|
| Research Design | 5 | 2019 | 5987 | 0.090 |
Why?
|
| Child, Preschool | 13 | 2013 | 41006 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 2 | 2009 | 2716 | 0.090 |
Why?
|
| Models, Biological | 3 | 2018 | 9583 | 0.090 |
Why?
|
| Point Mutation | 2 | 2008 | 1623 | 0.090 |
Why?
|
| Statistics, Nonparametric | 2 | 2008 | 2886 | 0.090 |
Why?
|
| DNA Methylation | 2 | 2021 | 4286 | 0.090 |
Why?
|
| Knowledge Bases | 1 | 2009 | 85 | 0.080 |
Why?
|
| Keratosis | 1 | 2009 | 81 | 0.080 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2009 | 100 | 0.080 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2007 | 379 | 0.080 |
Why?
|
| Trinidad and Tobago | 2 | 2018 | 11 | 0.080 |
Why?
|
| Genes, Reporter | 3 | 2015 | 1547 | 0.080 |
Why?
|
| Chromosomes, Human, Y | 1 | 2009 | 148 | 0.080 |
Why?
|
| Breast Feeding | 1 | 2017 | 1338 | 0.080 |
Why?
|
| Lead | 1 | 2014 | 852 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 2938 | 0.080 |
Why?
|
| RNA Helicases | 1 | 2009 | 142 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2022 | 5985 | 0.080 |
Why?
|
| History, 20th Century | 2 | 2020 | 2740 | 0.080 |
Why?
|
| Proteoglycans | 1 | 2012 | 835 | 0.080 |
Why?
|
| Salpingostomy | 1 | 2008 | 11 | 0.080 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2011 | 780 | 0.080 |
Why?
|
| Amino Acid Substitution | 3 | 2009 | 1791 | 0.080 |
Why?
|
| Somatomedins | 1 | 2009 | 192 | 0.080 |
Why?
|
| Delayed Graft Function | 1 | 2008 | 48 | 0.080 |
Why?
|
| Diabetes Complications | 2 | 2014 | 1359 | 0.080 |
Why?
|
| Time Factors | 7 | 2019 | 40075 | 0.080 |
Why?
|
| Mortality | 1 | 2020 | 2864 | 0.080 |
Why?
|
| DNA, Neoplasm | 5 | 2010 | 1758 | 0.080 |
Why?
|
| Endodeoxyribonucleases | 1 | 2009 | 165 | 0.080 |
Why?
|
| Occupational Exposure | 3 | 2014 | 1796 | 0.080 |
Why?
|
| Treatment Outcome | 12 | 2021 | 63114 | 0.080 |
Why?
|
| Leukemia, Myeloid | 3 | 2001 | 707 | 0.080 |
Why?
|
| Child | 19 | 2022 | 77709 | 0.080 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2008 | 129 | 0.080 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2012 | 417 | 0.080 |
Why?
|
| Social Medicine | 1 | 2008 | 62 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 216 | 0.080 |
Why?
|
| Cimicifuga | 1 | 2007 | 5 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1692 | 0.080 |
Why?
|
| Epidemiologic Research Design | 1 | 2011 | 367 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 8 | 2015 | 4803 | 0.070 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 349 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2020 | 13033 | 0.070 |
Why?
|
| RNA Interference | 2 | 2013 | 2889 | 0.070 |
Why?
|
| Brachial Plexus Neuritis | 2 | 1997 | 20 | 0.070 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 9438 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 1513 | 0.070 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2009 | 241 | 0.070 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 491 | 0.070 |
Why?
|
| Pandemics | 3 | 2022 | 8388 | 0.070 |
Why?
|
| Deafness | 1 | 2011 | 458 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2014 | 1180 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 3920 | 0.070 |
Why?
|
| Meat | 1 | 2010 | 592 | 0.070 |
Why?
|
| Nevus, Pigmented | 1 | 2009 | 219 | 0.070 |
Why?
|
| Arthralgia | 1 | 2011 | 456 | 0.070 |
Why?
|
| Educational Measurement | 1 | 2013 | 1210 | 0.070 |
Why?
|
| beta-Lactamases | 1 | 2008 | 306 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 2 | 2022 | 933 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2020 | 1142 | 0.070 |
Why?
|
| Heredity | 2 | 2017 | 154 | 0.070 |
Why?
|
| Regression Analysis | 5 | 2016 | 6459 | 0.070 |
Why?
|
| Arthritis | 1 | 2011 | 659 | 0.070 |
Why?
|
| Authorship | 1 | 2008 | 271 | 0.070 |
Why?
|
| Glutathione Peroxidase | 1 | 2006 | 255 | 0.070 |
Why?
|
| Cyclophosphamide | 2 | 2010 | 2242 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2503 | 0.070 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2005 | 105 | 0.070 |
Why?
|
| Nuclear Proteins | 4 | 2020 | 5853 | 0.070 |
Why?
|
| Peer Review, Research | 1 | 2008 | 329 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 10 | 4 | 2011 | 287 | 0.060 |
Why?
|
| Genes, p16 | 1 | 2005 | 157 | 0.060 |
Why?
|
| Guidelines as Topic | 2 | 2013 | 1405 | 0.060 |
Why?
|
| Evolution, Molecular | 3 | 2015 | 1940 | 0.060 |
Why?
|
| Poverty | 1 | 2017 | 2660 | 0.060 |
Why?
|
| Computational Biology | 4 | 2015 | 3521 | 0.060 |
Why?
|
| Receptors, Scavenger | 1 | 2005 | 121 | 0.060 |
Why?
|
| Fanconi Anemia | 2 | 2021 | 319 | 0.060 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2003 | 587 | 0.060 |
Why?
|
| Bioethics | 1 | 2006 | 116 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2011 | 1526 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3255 | 0.060 |
Why?
|
| Ultraviolet Rays | 2 | 2007 | 1060 | 0.060 |
Why?
|
| Bacteria | 1 | 2015 | 2114 | 0.060 |
Why?
|
| Proteome | 1 | 2014 | 1799 | 0.060 |
Why?
|
| Fruit | 1 | 2010 | 1142 | 0.060 |
Why?
|
| Vegetables | 1 | 2010 | 1182 | 0.060 |
Why?
|
| Fertility | 1 | 2009 | 781 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2649 | 0.060 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 262 | 0.060 |
Why?
|
| Longitudinal Studies | 4 | 2016 | 13989 | 0.060 |
Why?
|
| Histones | 1 | 2014 | 2599 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2008 | 981 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2011 | 658 | 0.060 |
Why?
|
| Los Angeles | 1 | 2024 | 238 | 0.060 |
Why?
|
| Transfection | 2 | 2021 | 5892 | 0.060 |
Why?
|
| Histone Acetyltransferases | 1 | 2005 | 336 | 0.060 |
Why?
|
| Disease | 1 | 2009 | 680 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2007 | 471 | 0.060 |
Why?
|
| Demography | 1 | 2008 | 1656 | 0.060 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 16689 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 2 | 2008 | 2170 | 0.060 |
Why?
|
| Mastectomy, Segmental | 2 | 2006 | 956 | 0.060 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2001 | 121 | 0.060 |
Why?
|
| Lod Score | 4 | 1998 | 614 | 0.060 |
Why?
|
| Gene Rearrangement | 1 | 2008 | 1179 | 0.050 |
Why?
|
| Kidney Transplantation | 2 | 2008 | 4251 | 0.050 |
Why?
|
| Control Groups | 1 | 2003 | 105 | 0.050 |
Why?
|
| Acyltransferases | 1 | 2004 | 294 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2007 | 547 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2012 | 3768 | 0.050 |
Why?
|
| Melanocytes | 2 | 2004 | 515 | 0.050 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2002 | 21 | 0.050 |
Why?
|
| Receptors, Erythropoietin | 1 | 2002 | 147 | 0.050 |
Why?
|
| Epidemiologic Factors | 1 | 2002 | 36 | 0.050 |
Why?
|
| Cell Cycle Proteins | 2 | 2015 | 3462 | 0.050 |
Why?
|
| Osteoporosis | 1 | 2012 | 1580 | 0.050 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2001 | 294 | 0.050 |
Why?
|
| Carcinogens | 1 | 2004 | 466 | 0.050 |
Why?
|
| Risk Management | 1 | 2006 | 571 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 3 | 2007 | 1681 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2004 | 1726 | 0.050 |
Why?
|
| Clothing | 1 | 2002 | 92 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2008 | 996 | 0.050 |
Why?
|
| Cell Line | 3 | 2011 | 15997 | 0.050 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2022 | 277 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 573 | 0.050 |
Why?
|
| Human Experimentation | 1 | 2002 | 127 | 0.050 |
Why?
|
| Forecasting | 3 | 2004 | 2951 | 0.050 |
Why?
|
| Data Collection | 1 | 2011 | 3341 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2021 | 64 | 0.050 |
Why?
|
| Exercise | 1 | 2018 | 5615 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2021 | 72 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2006 | 720 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2002 | 224 | 0.050 |
Why?
|
| Aging | 3 | 2012 | 8664 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2005 | 783 | 0.050 |
Why?
|
| Leukemia, Lymphoid | 1 | 2001 | 315 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2004 | 596 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2002 | 403 | 0.050 |
Why?
|
| Gene Expression | 4 | 2021 | 7799 | 0.050 |
Why?
|
| Sample Size | 3 | 2014 | 845 | 0.050 |
Why?
|
| Graft Survival | 2 | 2008 | 3737 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2001 | 173 | 0.050 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2001 | 670 | 0.050 |
Why?
|
| Minority Groups | 2 | 2024 | 1223 | 0.050 |
Why?
|
| Survivors | 1 | 2011 | 2291 | 0.050 |
Why?
|
| Waist-Hip Ratio | 1 | 2021 | 517 | 0.050 |
Why?
|
| Nicotine | 1 | 2005 | 681 | 0.050 |
Why?
|
| Research Subjects | 1 | 2002 | 239 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 305 | 0.040 |
Why?
|
| International Agencies | 2 | 2014 | 240 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2022 | 214 | 0.040 |
Why?
|
| Chromosome Deletion | 2 | 2004 | 1401 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2001 | 18111 | 0.040 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2016 | 197 | 0.040 |
Why?
|
| Cause of Death | 1 | 2010 | 3584 | 0.040 |
Why?
|
| Menarche | 2 | 2014 | 516 | 0.040 |
Why?
|
| Karyotyping | 2 | 1998 | 1243 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2001 | 623 | 0.040 |
Why?
|
| Hospitalization | 1 | 2019 | 10262 | 0.040 |
Why?
|
| AMP Deaminase | 1 | 1999 | 6 | 0.040 |
Why?
|
| Self Concept | 1 | 2005 | 1025 | 0.040 |
Why?
|
| Italy | 3 | 2006 | 832 | 0.040 |
Why?
|
| Africa, Northern | 1 | 2019 | 82 | 0.040 |
Why?
|
| Cheek | 1 | 1999 | 63 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 1997 | 197 | 0.040 |
Why?
|
| Homeodomain Proteins | 2 | 2022 | 2421 | 0.040 |
Why?
|
| Etoposide | 1 | 2001 | 641 | 0.040 |
Why?
|
| Confidentiality | 1 | 2023 | 612 | 0.040 |
Why?
|
| Ligases | 1 | 2000 | 333 | 0.040 |
Why?
|
| Trust | 1 | 2023 | 505 | 0.040 |
Why?
|
| Recurrence | 3 | 2014 | 8340 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2006 | 2290 | 0.040 |
Why?
|
| Middle East | 1 | 2019 | 219 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2015 | 1375 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 13695 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 595 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 426 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2006 | 1827 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1998 | 230 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2005 | 1547 | 0.040 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 638 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2002 | 450 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 11524 | 0.040 |
Why?
|
| Nomograms | 1 | 2020 | 228 | 0.040 |
Why?
|
| Parity | 2 | 2012 | 929 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2002 | 726 | 0.040 |
Why?
|
| Translocation, Genetic | 2 | 2001 | 1420 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2018 | 238 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2715 | 0.040 |
Why?
|
| Sex Characteristics | 2 | 2002 | 2585 | 0.040 |
Why?
|
| Research | 1 | 2006 | 1999 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2021 | 917 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2018 | 220 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 441 | 0.040 |
Why?
|
| Motivation | 2 | 2023 | 1971 | 0.040 |
Why?
|
| Xenobiotics | 1 | 1997 | 73 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 3752 | 0.040 |
Why?
|
| Quinone Reductases | 1 | 1996 | 18 | 0.040 |
Why?
|
| Commerce | 1 | 2002 | 592 | 0.040 |
Why?
|
| Laboratories | 1 | 2020 | 463 | 0.040 |
Why?
|
| Musculoskeletal Diseases | 1 | 2023 | 581 | 0.040 |
Why?
|
| Research Support as Topic | 2 | 2014 | 705 | 0.040 |
Why?
|
| Glucose | 2 | 2022 | 4397 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 1996 | 278 | 0.040 |
Why?
|
| International Cooperation | 2 | 2014 | 1420 | 0.040 |
Why?
|
| Stomach Neoplasms | 3 | 2018 | 1333 | 0.040 |
Why?
|
| Canada | 3 | 2006 | 2065 | 0.030 |
Why?
|
| Ethiopia | 1 | 2018 | 495 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 1996 | 106 | 0.030 |
Why?
|
| Introns | 3 | 2006 | 991 | 0.030 |
Why?
|
| Cadherins | 1 | 2001 | 907 | 0.030 |
Why?
|
| Brachial Plexus | 1 | 1997 | 163 | 0.030 |
Why?
|
| Primary Health Care | 2 | 2023 | 4558 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2011 | 9146 | 0.030 |
Why?
|
| Epoxide Hydrolases | 1 | 1996 | 122 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2003 | 1211 | 0.030 |
Why?
|
| Signal Transduction | 5 | 2021 | 23403 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1998 | 755 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 713 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2003 | 3420 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2022 | 868 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 352 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2021 | 2716 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2018 | 382 | 0.030 |
Why?
|
| Pregnancy | 4 | 2022 | 29144 | 0.030 |
Why?
|
| Minisatellite Repeats | 1 | 1996 | 165 | 0.030 |
Why?
|
| Genomic Imprinting | 1 | 1997 | 328 | 0.030 |
Why?
|
| Helicobacter Infections | 1 | 2018 | 386 | 0.030 |
Why?
|
| Alternative Splicing | 2 | 2013 | 1117 | 0.030 |
Why?
|
| Codon | 2 | 2009 | 611 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2008 | 4397 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 2538 | 0.030 |
Why?
|
| Racemases and Epimerases | 1 | 2015 | 113 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 1996 | 374 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 299 | 0.030 |
Why?
|
| DNA Probes | 1 | 2015 | 560 | 0.030 |
Why?
|
| Coenzyme A | 1 | 2014 | 39 | 0.030 |
Why?
|
| Acetyl Coenzyme A | 1 | 2014 | 74 | 0.030 |
Why?
|
| Nitriles | 1 | 2019 | 956 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2023 | 2682 | 0.030 |
Why?
|
| Apolipoprotein C-II | 1 | 1993 | 10 | 0.030 |
Why?
|
| Chromatin | 2 | 2018 | 2934 | 0.030 |
Why?
|
| Ovum | 1 | 1995 | 189 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 764 | 0.030 |
Why?
|
| Apolipoproteins C | 1 | 1993 | 59 | 0.030 |
Why?
|
| Foundations | 1 | 2014 | 94 | 0.030 |
Why?
|
| Nevus | 2 | 2006 | 204 | 0.030 |
Why?
|
| Benzamides | 1 | 2019 | 1379 | 0.030 |
Why?
|
| Databases, Factual | 3 | 2019 | 7729 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2003 | 2969 | 0.030 |
Why?
|
| Mammary Glands, Human | 1 | 2015 | 199 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2000 | 6365 | 0.030 |
Why?
|
| Government Agencies | 1 | 2014 | 156 | 0.030 |
Why?
|
| Co-Repressor Proteins | 1 | 2014 | 194 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2013 | 94 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2014 | 719 | 0.030 |
Why?
|
| Cholesterol | 1 | 2022 | 2917 | 0.030 |
Why?
|
| Interleukin-3 | 1 | 2014 | 444 | 0.030 |
Why?
|
| Genes, ras | 1 | 1996 | 690 | 0.030 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 3647 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 121 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 4751 | 0.030 |
Why?
|
| Patient Participation | 1 | 2002 | 1457 | 0.030 |
Why?
|
| Infant | 6 | 2012 | 35136 | 0.030 |
Why?
|
| Human Activities | 1 | 2012 | 25 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 1993 | 281 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2002 | 2942 | 0.030 |
Why?
|
| Poland | 1 | 2012 | 184 | 0.030 |
Why?
|
| Ethics, Research | 1 | 2014 | 191 | 0.030 |
Why?
|
| Apolipoprotein C-III | 1 | 1993 | 202 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 1995 | 641 | 0.030 |
Why?
|
| Apoptosis | 1 | 2008 | 9727 | 0.030 |
Why?
|
| Infant, Newborn | 5 | 2022 | 25625 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2014 | 486 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2006 | 5172 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2019 | 1533 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 3913 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 704 | 0.020 |
Why?
|
| Acetylation | 1 | 2014 | 1085 | 0.020 |
Why?
|
| Tubulin | 1 | 2015 | 695 | 0.020 |
Why?
|
| Counseling | 2 | 2000 | 1523 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 1157 | 0.020 |
Why?
|
| Replication Protein A | 1 | 2011 | 52 | 0.020 |
Why?
|
| Hepatitis B Vaccines | 1 | 2012 | 194 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2022 | 2531 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 300 | 0.020 |
Why?
|
| Sodium-Bicarbonate Symporters | 1 | 2010 | 32 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 577 | 0.020 |
Why?
|
| Immune System | 1 | 2016 | 805 | 0.020 |
Why?
|
| Minnesota | 1 | 1991 | 344 | 0.020 |
Why?
|
| Thiotepa | 1 | 2010 | 66 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2016 | 927 | 0.020 |
Why?
|
| Spermatozoa | 1 | 1995 | 625 | 0.020 |
Why?
|
| Computer Simulation | 3 | 2011 | 6196 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2010 | 133 | 0.020 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 148 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1998 | 1179 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2012 | 370 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 8949 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 2795 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2011 | 464 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2010 | 187 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 4462 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 1086 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 15295 | 0.020 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2009 | 61 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 6489 | 0.020 |
Why?
|
| Genetics, Medical | 1 | 2012 | 338 | 0.020 |
Why?
|
| Zebrafish | 1 | 2021 | 2994 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 1023 | 0.020 |
Why?
|
| Overweight | 1 | 2020 | 2371 | 0.020 |
Why?
|
| Georgia | 1 | 2009 | 186 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 604 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3952 | 0.020 |
Why?
|
| Delaware | 1 | 2008 | 16 | 0.020 |
Why?
|
| Nigeria | 1 | 2012 | 733 | 0.020 |
Why?
|
| ras Proteins | 1 | 2014 | 1060 | 0.020 |
Why?
|
| Oncogenes | 1 | 1995 | 1265 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 1799 | 0.020 |
Why?
|
| Universities | 1 | 2014 | 956 | 0.020 |
Why?
|
| Methyltransferases | 1 | 2011 | 367 | 0.020 |
Why?
|
| Massachusetts | 1 | 2021 | 8663 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 1613 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2010 | 377 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 11725 | 0.020 |
Why?
|
| Cytokines | 1 | 2003 | 7322 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 2803 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 2879 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 1813 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 2872 | 0.020 |
Why?
|
| Embryo Implantation | 1 | 2009 | 272 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2012 | 501 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 152 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2001 | 2734 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2008 | 241 | 0.020 |
Why?
|
| Genome | 1 | 2015 | 1808 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 789 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2012 | 658 | 0.020 |
Why?
|
| DNA Damage | 2 | 2011 | 2432 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 1534 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2001 | 12959 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 1873 | 0.020 |
Why?
|
| Anticarcinogenic Agents | 1 | 2008 | 253 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2018 | 3743 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 2183 | 0.020 |
Why?
|
| China | 1 | 2012 | 2248 | 0.020 |
Why?
|
| Medical Records | 1 | 2012 | 1413 | 0.020 |
Why?
|
| Focus Groups | 1 | 2011 | 1321 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 2012 | 804 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2008 | 381 | 0.020 |
Why?
|
| Mediterranean Region | 1 | 2005 | 47 | 0.020 |
Why?
|
| Endometrium | 1 | 2008 | 424 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 684 | 0.020 |
Why?
|
| Hirschsprung Disease | 2 | 1997 | 155 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1994 | 2967 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 1619 | 0.020 |
Why?
|
| Energy Metabolism | 2 | 2011 | 2899 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 3128 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2004 | 54 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 1411 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 6114 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 644 | 0.020 |
Why?
|
| Animals | 4 | 2021 | 168757 | 0.020 |
Why?
|
| Hormones | 1 | 2008 | 889 | 0.020 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 5751 | 0.010 |
Why?
|
| Mitochondria | 1 | 2017 | 3520 | 0.010 |
Why?
|
| Boston | 1 | 2017 | 9313 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 4420 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2010 | 2234 | 0.010 |
Why?
|
| Israel | 1 | 2006 | 796 | 0.010 |
Why?
|
| Pediatrics | 1 | 2018 | 3475 | 0.010 |
Why?
|
| Medicare | 1 | 2021 | 6566 | 0.010 |
Why?
|
| Social Environment | 1 | 2008 | 1023 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2014 | 8436 | 0.010 |
Why?
|
| Suppression, Genetic | 1 | 2003 | 196 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 1572 | 0.010 |
Why?
|
| Parents | 1 | 1996 | 3407 | 0.010 |
Why?
|
| Consent Forms | 1 | 2002 | 53 | 0.010 |
Why?
|
| Coercion | 1 | 2002 | 63 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 2915 | 0.010 |
Why?
|
| Caenorhabditis elegans | 1 | 2011 | 1419 | 0.010 |
Why?
|
| Disclosure | 1 | 2008 | 736 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2002 | 279 | 0.010 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2001 | 59 | 0.010 |
Why?
|
| Fertilization in Vitro | 1 | 2009 | 1284 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2002 | 374 | 0.010 |
Why?
|
| Catechols | 1 | 2001 | 61 | 0.010 |
Why?
|
| Quinones | 1 | 2001 | 76 | 0.010 |
Why?
|
| Recombination, Genetic | 2 | 1997 | 1586 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 1504 | 0.010 |
Why?
|
| Enzyme Stability | 1 | 2001 | 210 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 1770 | 0.010 |
Why?
|
| Guanine | 1 | 2001 | 274 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 4776 | 0.010 |
Why?
|
| Mice | 2 | 2021 | 81183 | 0.010 |
Why?
|
| Glioma | 1 | 2014 | 3401 | 0.010 |
Why?
|
| Hemorrhagic Disorders | 1 | 1998 | 36 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2008 | 2240 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 6773 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2002 | 880 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2010 | 3474 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2007 | 1928 | 0.010 |
Why?
|
| Digoxin | 1 | 1999 | 250 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1998 | 335 | 0.010 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 1999 | 111 | 0.010 |
Why?
|
| Estrogen Antagonists | 1 | 1998 | 152 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1998 | 803 | 0.010 |
Why?
|
| Acute Disease | 2 | 1998 | 7149 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2001 | 572 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 3966 | 0.010 |
Why?
|
| Adenosine Monophosphate | 1 | 1999 | 275 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2002 | 740 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2001 | 1801 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 2839 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2001 | 13102 | 0.010 |
Why?
|
| Diseases in Twins | 1 | 1998 | 449 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2009 | 8324 | 0.010 |
Why?
|
| Germany | 1 | 1998 | 862 | 0.010 |
Why?
|
| Diuretics | 1 | 1999 | 592 | 0.010 |
Why?
|
| Adenine | 1 | 2001 | 936 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1998 | 880 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 3610 | 0.010 |
Why?
|
| Heart Failure | 1 | 1999 | 10900 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2001 | 806 | 0.010 |
Why?
|
| Sex Chromosome Aberrations | 1 | 1994 | 114 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 9959 | 0.010 |
Why?
|
| Ligands | 1 | 2001 | 3282 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 3846 | 0.010 |
Why?
|
| Kallmann Syndrome | 1 | 1994 | 140 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 15165 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1998 | 1880 | 0.010 |
Why?
|
| Fundus Oculi | 1 | 1994 | 473 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2001 | 949 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 6314 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 8863 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1999 | 851 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1999 | 1869 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1999 | 1518 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 6487 | 0.010 |
Why?
|
| Models, Theoretical | 2 | 1995 | 3589 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2001 | 2564 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 11727 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2009 | 6882 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 13815 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 8642 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1999 | 4199 | 0.010 |
Why?
|
| Causality | 1 | 1995 | 1275 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1995 | 2373 | 0.000 |
Why?
|
| Myocardium | 1 | 1999 | 4776 | 0.000 |
Why?
|
| Coronary Disease | 1 | 1999 | 6077 | 0.000 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2001 | 5221 | 0.000 |
Why?
|
| Skin | 1 | 1994 | 4364 | 0.000 |
Why?
|